The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04327674|
Recruitment Status : Unknown
Verified March 2020 by University of Aarhus.
Recruitment status was: Recruiting
First Posted : March 31, 2020
Last Update Posted : March 31, 2020
COVID is a major health problem causing massive capacity problems at hospitals. Rapid and accurate diagnostic workflow is of paramount importance. Access to radiological diagnostics tools such as x-ray or computed tomography of the chest are limited even in high-resource settings.
Focused lung ultrasound, FLUS, is a point-of-care diagnostic tool that allows rapid and on-site assessment of lung abnormalities. No transportation of the patient is required thus lowering risk of spreading SAR-CoV- inside the hospital.
This study aims to explore the diagnostic value of FLUS in the COVID-19 pandemic and to explore if FLUS findings can predict risk of respiratory failure.
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||375 participants|
|Target Follow-Up Duration:||1 Month|
|Official Title:||The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19|
|Actual Study Start Date :||March 14, 2020|
|Estimated Primary Completion Date :||May 15, 2020|
|Estimated Study Completion Date :||May 15, 2020|
- FLUS findings and respiratory failure [ Time Frame: Up to 3 months. ]Analysis of FLUS related to risk of development of respiratory failure.
- FLUS findings and chest x-ray. [ Time Frame: Up to 3 months. ]Analysis of FLUS related to risk of result of chest x-ray
- FLUS findings and admission to intensive care. [ Time Frame: Up to 3 months. ]Analysis of FLUS related to risk of intensive care admission
- FLUS findings and SAR-CoV-2 PCR-test result. [ Time Frame: Up to 3 months. ]Analysis of FLUS related to result from SAR-CoV-2 PCR-test
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04327674
|Contact: Søren H Skaarupemail@example.com|
|Lungemedicinsk Forskningsafdeling. Aarhus University Hospital||Recruiting|
|Aarhus, Denmark, 8000|
|Contact: Søren Helbo SH Skaarup, MD +45 28911869 firstname.lastname@example.org|
|Contact: Jesper Weile|
|Principal Investigator:||Søren H Skaarup||Aarhus Universitets Hospital|